Guirlene Clervoix
Psychiatric/Mental Health · New Castle, DENPI 1730653833
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $933, 4.3 times the $215 reported in 2021.
Across 65 payments — averaging $39.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$249
- Gilead$206
- AstraZeneca$197
- Axsome Therapeutics, Inc.$160
- Novo Nordisk$160
- Lilly USA, LLC$147
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,559100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $249 |
| Gilead | 2 | $206 |
| AstraZeneca | 6 | $197 |
| Axsome Therapeutics, Inc. | 3 | $160 |
| Novo Nordisk | 4 | $160 |
| Lilly USA, LLC | 4 | $147 |
| Astellas Pharma US Inc | 1 | $120 |
| Neurocrine Biosciences, Inc. | 5 | $108 |
| Rigel Pharmaceuticals, Inc. | 1 | $105 |
| Cipher Pharmaceuticals US LLC | 1 | $99 |
| Abbott | 1 | $97 |
| Johnson & Johnson | 2 | $95 |
| Braeburn Inc. | 1 | $92 |
| Alkermes, Inc. | 4 | $84 |
| Boehringer Ingelheim | 4 | $68 |
| Tactile Systems Technology Inc | 1 | $67 |
| AbbVie | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 1 | $62 |
| Neurelis, Inc. | 1 | $59 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $49 |
| Merck | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Exact Sciences | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Bayer | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Indivior Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,559 in reported general payments places this provider in the 80th percentile of 177 psychiatric/mental health providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trazodone Hcl | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in New Castle
- Michael KolodgieNew Castle$3K
- Oluwadamilare ShoneyeNew Castle$3K
- Cheryl GrantNew Castle$2K
- Tracee SherlockNew Castle$2K
- Ronald TyreeWilmington$59K
- Ericka Taylor-DanielDover$39K
- Cindy CunninghamDover$14K
- Kameka HartNewark$10K
- Jenika MilesWilmington$8K
- Catherine DotyNewport$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.